NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annu...( Evaluation of Neurologic Safety follo...)

Evaluation of Neurologic Safety following Treatment with Qutenza(TM) (NGX-4010)

Identification of Impact of PHN and PDN on Health Care Costs

SAN MATEO, Calif., April 29 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today the presentation of two posters at the 61st Annual American Academy of Neurology (AAN) meeting in Seattle, Washington. These posters, titled "Neurologic Safety of Treatment with NGX-4010, a High-Concentration Capsaicin Patch, in Patients with Postherpetic Neuralgia" and "Impact of Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy on Health Care Costs," summarized the results of two sets of analyses.

"Neurologic Safety of Treatment with NGX-4010, a High-Concentration Capsaicin Patch, in Patients with Postherpetic Neuralgia," was led by Miroslav Backonja, MD, of the University of Wisconsin-Madison, and Jeffrey Tobias, MD, Chief Medical Officer of NeurogesX. The integrated analyses examined the effects of Qutenza(TM) (NGX-4010) treatment on neurologic function in patients with posteherpetic neuralgia (PHN). Combined data from four 12-week, controlled studies in over 700 patients showed that there appeared to be no detrimental neurological effects after treatment with Qutenza as measured by light brush, pinprick, vibration and warmth sensations compared with controls. In addition, combined data from almost 300 patients evaluated in two open-label, 1-year repeat treatment studies appeared to show no detrimental neurologic effects of repeated treatment with Qutenza. The most common adverse reactions observed in these clinical trials were transient application site reactions (pain and/or erythema) that were mostly mild to moderate in intensity.